The first hearing of the case filed against the pharmaceutical company AstraZeneca due to the delays in the European Union’s supply of new types of corona virus vaccine was held.
The EU Commission and AstraZeneca lawyers participated in the case at the Brussels Magistrates Court.
Following the hearing of the parties, the court decided to hold the next hearing on 26 May.
Speaking to the press after the hearing, AstraZeneca lawyer Judge Boularbah expressed deep regret about the company’s decision to initiate a legal process regarding the Covid-19 vaccine agreement.
Boularbah stated that they hoped to resolve the dispute as soon as possible.
“We want a fast enough dose in accordance with the convention,” EU Commission Spokesperson Stefan de Keersmaecker said at the daily press conference.
“WE WANT THE DOSE ABOUT US”
Pointing out that the next hearing will be held on May 26, Keersmaecker said, “Our aim is to provide the doses we believe to be our right.”
The agreement of the EU with AstraZeneca included the provision of 300 million doses of vaccine and the option to purchase an additional 100 million doses if requested.
While the EU expected 120 million doses of vaccine in the first quarter of the year, the company was only able to provide 30 million doses. In the second quarter, the EU side was expecting 180 million doses, but the company announced that it could provide 70 million doses during this period.
The EU Commission claims that AstraZeneca should also send vaccines produced at its UK facilities to EU countries.
The firm argues that while not welcoming this, they do not commit to the EU in concrete terms of supply amounts and dates.
EU AIMS TO EXCEED 70 PERCENT OF ADULTS BY THE END OF SUMMER
The EU aims to vaccinate 70 percent of the adult population by the end of the summer and is trying to accelerate vaccine supply for this purpose.
The EU with a population of 450 million, including options, to receive 600 million doses of vaccine with BioNTech-Pfizer, 400 million with AstraZeneca, 300 million with Sanofi-GSK, 400 million with Johnson & Johnson company, 405 million with CureVac and 460 million with Moderna. has a contract for.
The European Medicines Agency (EMA) has approved the use of 4 vaccines in EU countries so far. These include vaccines manufactured by BioNTech-Pfizer, Moderna, AstraZeneca and Johnson & Johnson.